Compare GSK plc (GSK) vs Iron Mountain Inc (IRM) Price & Performance

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Iron Mountain (IRM) trades at $124.67, up 2.56% today, with a bearish technical signal but strong recent earnings beats. Revenue grew to $6.90B in 2025, though net margins compressed to 2.09%. The stock is supported by a 65% analyst buy rating and a $141.50 consensus target, with institutional interest highlighted by recent purchases. Key risks include high debt levels, with a debt-to-asset ratio of 79.04% in 2025.

Outlook remains mixed; robust data center growth and dividend yield near 2.8% offer upside, but elevated valuation (P/E 86.8) and persistent negative shareholder equity warrant caution. Earnings momentum from Q2 2026 beat provides near-term support, yet debt servicing and competitive pressures pose headwinds for sustained gains.